KRAS mutation confers resistance to antibody‐dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Cetuximab is a chimeric IgG1 monoclonal antibody (mAb) that targets the extracellular domain of epidermal growth factor receptor (EGFR). Oncogenic KRAS mutations in tumors have been shown to be a negative predictor of the response of colorectal cancer (CRC) to cetuximab treatment. Cetuximab exerts its therapeutic effects through several mechanisms including antibody‐dependent cellular cytotoxicity (ADCC). However, the influence of KRAS mutations on cetuximab‐mediated ADCC is not fully understood. Here, we investigated cetuximab‐mediated ADCC in two pairs of isogenic CRC cells with or without a KRAS mutation. Peripheral blood mononuclear cells (PBMCs) from healthy volunteers and NK92, a natural killer (NK) cell line that exogenously expresses FcγRIIIa (CD16a), were used as effector cells. In an ADCC assay, perforin‐dependent target cell lysis was not affected by the KRAS mutation status. On the other hand, perforin‐independent ADCC was observed only in CRC cells with wild‐type KRAS, but not in cells with mutant KRAS. Neutralizing experiments revealed that the Fas‐Fas ligand (FasL) interaction was responsible for the induction of apoptosis and perforin‐independent ADCC. Furthermore, the presence of effector cells clearly enhanced the growth‐inhibitory effect of cetuximab only in CRC cells with wild‐type KRAS, but not in those with mutant KRAS. These findings suggest that ADCC is an important mode of action of cetuximab and that KRAS mutation impairs the therapeutic effect exerted by cetuximab‐mediated ADCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · cited 3×
“Several retrospective analyses have clearly demonstrated that activating mutations of KRAS confer resistance to cetuximab therapy in patients with mCRC.(5,19,20) Given the results of these analyses, the use of cetuximab has been restricted to mCRC patients with wild-type KRAS tumors.”
BackgroundK-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144 · cited 1×
“KRAS activating mutations have been reported in 40% of mCRC patients.(18) Several retrospective analyses have clearly demonstrated that activating mutations of KRAS confer resistance to cetuximab therapy in patients with mCRC.”
BackgroundA Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063 · cited 1×
“Although KRAS codon 12 mutations occur predominantly in pancreatic cancer, CRC has both codon 12 (mainly G12D and G12V) and codon 13 (G13D) mutations.(37) At present, treatment with anti-EGFR is not recommended for CRC patients with tumors carrying KRAS codon 12 or 13 mutations.”
BackgroundCetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981
Benvenuti, S., Sartore-Bianchi, A., Di Nicolantonio, F., Zanon, C., Moroni, M., Veronese, S., Siena, S., & Bardelli, A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4158 · Cited by 830 · cited 2×
“However, many studies have reported that the cetuximab-mediated direct inhibition of cell growth is limited.(17,21,26) To date, little is known regarding the association of KRAS mutations with ADCC.”
BackgroundBibeau, F., Lopez-Crapez, E., Di Fiore, F., Thezenas, S., Ychou, M., Blanchard, F., Lamy, A., Penault-Llorca, F., Frébourg, T., Michel, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0463 · Cited by 521 · cited 1×
“better clinical outcome to rituximab (anti-CD20),(12) trastuzumab (anti-HER2)(13) and cetuximab.(14) Cetuximab-mediated ADCC was reportedly induced by a low antibody concentration in various cancer cell lines that exhibited almost no direct growth-inhibitory effect of cetuximab, despite the presence of a high cetuxima…”
BackgroundJhawer, M., Goel, S., Wilson, A. J., Montagna, C., Ling, Y.-H., Byun, D.-S., Nasser, S., Arango, D., Shin, J., Klampfer, L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5659 · Cited by 460 · cited 2×
“However, the inhibitory effect of cetuximab on cell growth is reportedly limited even in some KRAS-wild-type cell lines.(23) On the other hand, little is known about the impact of KRAS mutations on cetuximabmediated ADCC.”
BackgroundTejpar, S., Celik, I., Schlichting, M., Sartorius, U., Bokemeyer, C., & Van Cutsem, E. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.2592 · Cited by 353 · cited 1×
“Recently, retrospective analyses of large clinical trials have suggested that patients with KRAS G13D-mutated tumors seem to obtain clinical benefits from treatment with cetuximab.(39,40) Further preclinical understanding of the mechanisms underlying these differential efficacies and prospective clinical trials are co…”
BackgroundRoberti, M. P., Barrio, M. M., Bravo, A. I., Rocca, Y. S., Arriaga, J. M., Bianchini, M., Mordoh, J., & Levy, E. M. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1360-2 · Cited by 51
Cited by
Monoclonal Antibodies in Cancer Therapy
Zahavi, D., & Weiner, L. (2020) · Antibodies · doi:10.3390/antib9030034 · Cited by 831
Overcoming resistance to tumor-targeted and immune-targeted therapies
Aldea, M., Andre, F., Marabelle, A., Dogan, S., Barlesi, F., & Soria, J.-C. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1638 · Cited by 311
Beyond KRAS Status and Response to Anti-EGFR Therapy in Metastatic Colorectal Cancer
Perkins, G., Pilati, C., Blons, H., & Laurent-Puig, P. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.66 · Cited by 22
Kasai, G., Shioya, S., Kobe, M., Kobayashi, S., Takamatsu, S., Makabe, K., Kumagai, I., Sode, K., & Asano, R. (2025) · Biochemical Engineering Journal · doi:10.1016/j.bej.2025.109776 · Cited by 5
Metadata
- Authors
- Nakadate, Y., Kodera, Y., Kitamura, Y., Shirasawa, S., Tachibana, T., Tamura, T., & Koizumi, F.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2013-11-04
- Volume
- 134
- Issue
- 9
- Pages
- 2146-2155
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W1937083157
- Cited by
- 43
- References
- 11
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.